Clinical trials: Digestive System Neoplasms
Peritoneal Carcinomatosis, Gastric Cancer
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients.
- Trial name
- GASPACCO (NCT04595929)
- Testing
- Staging laparoscopy, 5-Fluorouracil, Leucovorin
- Where
- Russia
- Volunteers
- 304 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Gastric Cancer
Annual Hospital Volume and and Short-term Postoperative Outcomes After Gastric Cancer Resection
The effect of centralisation measures on the operative outcomes after gastric cancer resection in Switzerland has not been highlighted yet.
- Trial name
- NCT07072429
- Testing
- Gastric cancer resection
- Where
- Switzerland
- Volunteers
- 3,112 people
- Sponsor
- Cantonal Hospital of St. Gallen
Rectal Cancer
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102).
- Trial name
- TASLARC (NCT05965531)
- Testing
- Trifluridine/Tipiracil, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Sun Yat-sen University
FAP, Familial Adenomatous Polyposis
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis
The aim of this study is to evaluate the potential of BHB supplementation as a novel strategy to impede the development and progression of intestinal adenomas in individuals with FAP, thus potentially reducing the need for…
- Trial name
- BHB-FAP (NCT06578637)
- Testing
- R-1,3-Butanediol (10G-A), R-1,3-Butanediol (20G-A), R-1,3-Butanediol (30G-A)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Rectal Cancer, Pancreatic Cancer
Multimodal Imaging in Rectal Cancer & Pancreatic Cancer
Most digestive cancers show (over)expression of the tumour marker carcinoembryonic antigen (CEA). Therefore, interest in CEA-targeting tracers has increased over the past years.
- Trial name
- MIRCA & MIPAC (NCT06395337)
- Testing
- [111In]In-DOTA-ANTI-CEA antibody injection, SPECT/CT scan, Resection surgery
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Surgical Wound Infection, Pancreatic Neoplasms
The Use of Wound Protector in Whipple's Procedure With Intrabiliary Stent
Background: There are no published studies regarding the use of wound protectors in the context of surgical site infection (SSI) rates among patients receiving a pancreatoduodenectomy (Whipple) with preoperatively placed…
- Trial name
- NCT01836237
- Testing
- Alexis - a wound protector
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- University of Calgary
Advanced Solid Tumor, Gynecologic Cancer
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04691375
- Testing
- PY314, Combination Therapy: PY314 + Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 86 people
- Sponsor
- Ikena Oncology
Gastrointestinal Neoplasms, Gastrointestinal Disease
Endoscopic Resection Multicenter Registry
This is a retrospective and prospective multicenter registry to collect long-term data (1 year) on patients who have or will undergo Endoscopic resection such as EMR, ESD, EFTR, STER, etc.
- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Disease, Gastric Cancer, Gastric Neoplasm
- Trial name
- NCT03065257
- Testing
- Endoscopic Resection
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Colorectal Cancer, Colorectal Surgery
Nutritional Supplementation to Improve Colorectal Cancer Surgery
This study aims to explore the effectiveness of perioperative Oral Nutritional Supplementation (ONS) combined with an optimized, tailored diet in reducing the risk of postoperative complications and improving the nutritional…
- Trial name
- NUTRICOLOR (NCT07599501)
- Testing
- Diet Optimization (DO), Oral Nutritional Supplement (ONS)
- Where
- Italy
- Volunteers
- 190 people
- Sponsor
- Istituto Clinico Humanitas
Colorectal Neoplasms, Gastrointestinal Stromal Tumors
The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
Regorafenib is a novel oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinases. It is currently registered for GIST and mCRC.
- Trial name
- REGORA (NCT02800330)
- Testing
- Esomeprazole 40mg concomitantly, Esomeprazole 40mg before, Regorafenib 160mg or 120mg
- Where
- Netherlands
- Volunteers
- 31 people
- Sponsor
- Erasmus Medical Center
Solid Tumors, Soft Tissue Sarcoma
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
This is a pilot study of LTLD with MR-HIFU hyperthermia followed by ablation in subjects with refractory/relapsed solid tumors.
- Conditions
- Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm
- Trial name
- NCT04791228
- Testing
- Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
- Where
- United States
- Sponsor
- Children's National Research Institute
Biliary Tract Carcinoma
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma.
- Trial name
- NCT04924062
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 22 sites in China
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreas Cancer, Biliary Tract Cancer
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
The primary objective of this study is to evaluate the ability to recruit and retain participants, and to successfully conduct a psilocybin-based protocol, for a study of the treatment of distress related to stage IV or…
- Conditions
- Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
- Trial name
- NCT05220046
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Nebraska
Esophageal Cancer, Photodynamic Therapy
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
The objective of the present clinical trial is to assess the efficacy of photodynamic therapy (PDT) employing hematoporphyrin injection in the management of recurrent or residual superficial esophageal carcinoma.
- Trial name
- NCT06437288
- Testing
- photodynamic therapy
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
DPYD Gene Mutation, Gastrointestinal Cancer
Nudge Strategies for DPYD Testing in Patients With Gastrointestinal Cancers Treated With Fluoropyrimidines
5-fluorouracil and capecitabine, sometimes called 5-FU, fluoropyrimidines, or Xeloda are a type of chemotherapy. Many people have side effects from these drugs like nausea, diarrhea, or blood problems.
- Conditions
- DPYD Gene Mutation, Gastrointestinal Cancer, Health Care Seeking Behavior
- Trial name
- DPYD Nudges (NCT06559462)
- Testing
- Focus Group, Discrete Choice
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Gastric Cancer
Gastric Decompression After Sub-total Gastrectomy
The purpose of this study is to test the utility of the nasogastric tube, which is used to decompress and as "guardian" of gastro-jejunal anastomosis, in patients undergoing distal subtotal gastrectomy for gastric cancer with…
- Trial name
- NCT01073046
- Testing
- Naso-Gastric/Jejunal Tube
- Where
- Italy
- Volunteers
- 276 people
- Sponsor
- Catholic University, Italy
Colorectal (Colon or Rectal) Cancer
Colorectal Cancer Screnning Colonoscopy Under Hypnosis
Through this study, the effectiveness of hypnosis in the realization of a colonoscopy for the detection of colorectal cancer will be evaluated
- Trial name
- CODEPICCH (NCT05051046)
- Testing
- Colonoscopy under hypnosis
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Tours
Colorectal Neoplasms
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.
- Trial name
- NCT00460603
- Testing
- bevacizumab, AG-013726, AG-013736 (axitinib)
- Where
- 106 sites in United States
- Volunteers
- 187 people
- Sponsor
- Pfizer
Barrett's Esophagus
Barrett's Esophagus - 315 - 3 Way Cross Over
This study evaluates PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue. All patients will have a baseline endoscopy with multiple biopsies.
- Trial name
- NCT00637988
- Testing
- Esomeprazole, Aspirin, Rofecoxib
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Tumors, Ovarian Cancer
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Primary Objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 and ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant…
- Conditions
- Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT05431582
- Testing
- ZN-c3, Bevacizumab, Pembrolizumab
- Sponsor
- M.D. Anderson Cancer Center